

# Bioanalytical Systems Inc.

Bioanalytical Systems Inc., 2701 Kent Ave., West Lafayette, 47906, provides contract-research services to the pharmaceutical industry. In the fiscal first quarter, which ended Dec. 31, 2016, Bioanalytical earned \$17,000, or zero cents per share, on revenue of \$6.2 million. In the same period a year earlier, the company lost \$506,000, or 6 cents per share, on revenue of \$4.9 million. Bioanalytical shares trade on NASDAQ under the ticker BASI. Information for Proxy Corner was taken from Yahoo Finance and the company's proxy statement dated Feb. 3, 2017.

<b>VALUE</b>	<b>3/16/17</b>	<b>3/1617</b>
Shares of common stock outstanding	8.1 million	8.1 million
Market value of one common share	\$1.48	\$1.40
Market value of common stock	\$11.99 million	\$11.34 million

## **NOTEWORTHY CONTROL**

### **Peter and Candice Kissinger**

Number of shares: 1,275,767  
Percent of shares: 15.7

### **Seth Hamot**

Number of shares: 636,621  
Percent of shares: 7.9

## **EXECUTIVE COMPENSATION**

	<b>Total '16 compensation</b>	<b>Salary Bonus</b>	<b>Stock and option grants (1)</b>	<b>All other pay (2)</b>	<b>% change (3)</b>
<b>Jacqueline Lemke</b> CEO and president	\$305,558	<u>\$296,400</u> \$0	\$0	\$9,158	-7.2%
<b>James Bourdage</b> vice president	\$174,038	<u>\$174,038</u> \$0	\$576	\$6,000	2.4%
<b>Philip Downing</b> vice president	\$148,444	<u>\$148,444</u> \$0	\$0	\$0	-3.6%

(1) Grant date fair value of stock and options awards, as calculated in company's proxy statement in its grant of plan-based awards table.

(2) Includes non-equity incentive plan compensation, above-market or preferential earnings on deferred compensation and all other annual compensation.

(3) Percentage increase or decrease in executive's total compensation vs. previous year.

## **DIRECTORS**

### **Richard Johnson, 71**

Occupation: executive scientific consultant  
Number of shares: 25,000  
Previous year: 25,000

### **Larry Boulet, 69**

Occupation: former senior audit partner for PricewaterhouseCoopers  
Number of shares: 30,000  
Number of shares: 30,050

### **Wendy Perrow, 58**

Occupation: CEO of AsclepiX Therapeutics  
Number of shares: 0  
Number of shares: 0